Novogen Ltd. (Nasdaq: NVGN) announced that TRXE-009 demonstrated potential to kill brain cancer stem cells sending the stock price soaring $1.09 to $3.61.
Novogen's TRXE-009 shows potential
March 04, 2015 at 13:14 PM EST
Novogen's TRXE-009 shows potentialMarch 04, 2015 at 13:14 PM EST
Novogen Ltd. (Nasdaq: NVGN) announced that TRXE-009 demonstrated potential to kill brain cancer stem cells sending the stock price soaring $1.09 to $3.61.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|